1. Is Parabolic Drugs Ltd a good quality company?
Data is not available for this company.
2. Is Parabolic Drugs Ltd undervalued or overvalued?
The key valuation ratios of Parabolic Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is Parabolic Drugs Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Parabolic Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||14%||13.9%||11.3%||10.5%||-8.8%||-7.7%||-34.7%||-75.3%||-41.9%||-30.8%||-|
|Value Creation Index ⓘ||0||-0||-0.2||-0.3||-1.6||-1.6||NA||NA||NA||NA||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||30.2%||20.6%||49.1%||-17.2%||-42.8%||-47.1%||-67.4%||-2.5%||-1.5%||-|
|Adj EPS ⓘ||7.5||10.9||8.4||8.3||-22.9||-22.4||-61.3||-76.1||-17.4||-9.2||-3.2|
|YoY Gr. Rt. %||-||45.9%||-23.1%||-1.4%||-376.4%||NA||NA||NA||NA||NA||-|
|BVPS (₹) ⓘ||25||32.5||61.2||69.2||17.2||3.1||-50.6||-121.8||-134.2||-141.3||-152|
|Adj Net Profit ⓘ||24.2||40.8||52.1||51.3||-142||-139||-379||-471||-108||-56.9||-20|
|Cash Flow from Ops. ⓘ||-38.3||-30.9||2.5||207||-111||27.9||-3.9||89.6||1.7||3||-|
|Debt/CF from Ops. ⓘ||-6.9||-13.6||186.5||2.7||-7||30.1||-242.8||10.9||593.3||326.2||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||-202.3%||NA||NA||NA|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||23.7||28.7||19.4||12.7||-38.9||-57.3||5767.8||107.4||14.6||7||2.2|
|Op. Profit Mgn % ⓘ||15.2||18||18.1||17||-14.6||-29.9||-55.1||-437.9||-104.1||-39||0|
|Net Profit Mgn % ⓘ||6.1||7.9||8.4||5.6||-18.5||-31.7||-163.6||-623.4||-146||-78.4||0|
|Debt to Equity ⓘ||2.5||3.5||1.3||1.3||7.3||43.6||-3.1||-1.3||-1.2||-1.1||-|
|Working Cap Days ⓘ||239||268||329||297||327||462||757||1,282||647||484||0|
|Cash Conv. Cycle ⓘ||173||165||189||125||168||276||535||1,038||214||5||0|
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
|TTM EPS (₹)||-3.2||-9.3|
|TTM Sales (₹ Cr.)||0||73.2|
|BVPS (₹.) ⓘ||-152||0|
|Reserves (₹ Cr.) ⓘ||-1,000||-943|
|From the Market|
|52 Week Low / High (₹)||1.05 / 5.70|
|All Time Low / High (₹)||0.59 / 79.00|
|Market Cap (₹ Cr.)||35.3|
|Equity (₹ Cr.)||61.9|
|Face Value (₹)||10|
|Industry PE ⓘ||37.3|
Parabolic Drugs was incorporated on February 22, 1996 under the Companies Act, 1956, with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. The company is promoted by Pranav Gupta, Vineet Gupta, PNG Trading Private Limited (PNG) and Parabolic Infrastructure Private Limited (PIPL).
At present, the company is currently own and operate two manufacturing facilities at Derabassi, Punjab, and Panchkula, Haryana. It commenced commercial operations in February 1998 by setting up a unit at Sundhran, Derabassi, to manufacture SSPs. Currently, it has six units at Sundhran, Derabassi, for manufacturing the oral and sterile range of Cephalosporin APIs and intermediates. The facility at Sundhran, Derabassi, is WHO-GMP and ISO-14001 certified.
Parabolic Drugs started its second facility at Panchkula in fiscal year 2005. Currently, the Panchkula facility has two units manufacturing SSPs and API intermediates such as 6-APA. It is also in the process of setting up a custom synthesis and research and development (R&D) centre at Barwala, Haryana, for development and scale-up of new APIs and APIs intermediates in all therapeutic segments, including non-antibiotic products. This facility is expected to commence operations in the last quarter of fiscal year 2010, to focus on providing contract research services to innovator companies.
In addition, the company is in the process of setting up another manufacturing facility at Chachrauli, Derabassi, to manufacture the non-antibiotic range of APIs, which is expected to commence commercial operations in the third quarter of fiscal year 2011.
The companyâ€™s product portfolio presently comprises 42 APIs and seven API intermediates which are marketed and exported domestically in the market. It supplies its products to approximately 45 countries, including regulated markets. It has filed 15 dossiers with the relevant regulatory authorities to increase its penetration in the regulated markets. This includes six DMFs filed with the USFDA, one DMF filed with the Bureau of Pharmaceutical Sciences, Canada and eight dossiers filed with the EDQM, including two for which it has received Certificates of Suitability (CoS) from the EDQM, for supplying Amoxicillin and Flucloxacillin Sodium for the European markets. Currently, it supplies 6-APA from its Panchkula facility for the US markets conforming to the regulations prescribed by the USFDA.
The company has an established R&D setup which comprises chemical and analytical research laboratories at our facility at Sundhran, Derabassi. The companyâ€™s focus is on developing non-infringing processes for new molecules for expansion of its product portfolio, existing process improvements and production cost efficiencies. Its R&D department has led the company to successfully launch additional sterile and oral products over the years. During fiscal year 2010, products such as Ceftazidime, Cefotiam, Ceftizoxime and Cephalothin were launched to further widen its product range.
It has made eight applications for the process patents, of which seven patent applications have been filed with the Indian Patent Office, and one international process patent for manufacturing Cefuroxime Axetil filed under the PCT.
Business area of the company
The company is presently engaged in the manufacturing, including contract manufacturing, of APIs and API intermediates for the domestic market as well as for exports to international markets, including regulated markets.
Subsidiary of the company
Parabolic Labs: The company was incorporated as a private limited company under the Companies Act, 1956 on November 21, 2007 and received its Certificate for Commencement of business on January 3, 2008.
Parabolic Labs is authorized to engage in the business of manufacturing, buying, selling, repacking C&F agents, manipulating, importing, exporting, distributing and trading in or otherwise dealing in all types of basic drugs, pharmaceuticals, medicines, preparations, compounds, spirits, patent medicines, drugs, mineral waters, 96 chemicals, petrochemicals, etc., to carry on work relating to contract research on drugs manufactured by other manufacturers and to carry on research for the development of new drugs.